Europe Neurological Biomarkers Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product (Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Others); Application (Alzheimer's Disease, Parkinson's Disease, Schizophrenia, Huntington's Disease, Spinal Muscular Atrophy, Others); End User (Pharmaceutical and Biotechnology Companies, Clinical Diagnostics, Research Organizations)
Market Introduction
Biomarkers are disease-specific indicators. Advancements in biotechnology have enabled the measurement of specific biomarkers responsible for various neurological diseases that was not possible earlier. The rising adoption of these biomarkers have helped in the early detection, less invasive diagnosis and faster drug development for neurological disorders.
Get more information on this report :
Market Overview and Dynamics
The European neurological biomarkers market is expected to reach US$ 3,062.94 Mn in 2027 from US$ 1,221.15 Mn in 2019. The market is estimated to grow with a CAGR of 12.4% from 2020-2027. The market is expected to witness a substantial growth due to driving factors such as rising prevalence of neurological disorders and progressive research in neurological biomarkers. However, the complications associated with the use of neurological biomarkers are expected to hinder the market growth.
Key Market Segments
Based on product, in 2019, the genomic biomarkers segment held the largest share of the market and is expected to grow at the fastest CAGR during the forecast period. This segment is likely to witness a lucrative growth owing to increasing awareness among consumers regarding benefits of genetic medicines as well as technological advancements in the field of neurological biomarkers. In addition, the trend shift towards adoption of gene counseling and genetic analysis for diagnostic purposes is also likely to augment the growth of the segment. The genetic biomarkers are significant modalities that directs towards a more personalized approach of predispositions and medical analysis.
Major Sources and Companies Listed
Some of the major primary and secondary sources for Neurological Biomarkers market included in the report are, World Health Organization (WHO), National Health Service (NHS), Biomarker Research and Imaging for Neuroscience (BRAIN), European Commission (EC), and others
Reasons to buy the report
- To understand the neurological biomarkers market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for neurological biomarkers market
- Efficiently plan M&A and partnership deals in neurological biomarkers market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form neurological biomarkers market
- Obtain market revenue forecast for market by various segments from 2019 to 2027 in Europe region.
NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION
By Product
- Proteomics Biomarker
- Genomics Biomarker
- Metabolomics Biomarker
- Imaging Biomarker
- Others
By Application
- Alzheimer’s Disease
- Parkinson's Disease
- Schizophrenia
- Huntington's Disease
- Spinal Muscular Atrophy
- Others
By End User
- Pharmaceutical and Biotechnology Companies
- Clinical Diagnostics
- Research Organizations
By Geography
• Europe
- Germany
- UK
- France
- Italy
- Spain
Company Profiles
- Thermo Fisher Scientific, Inc
- Myriad Genetics
- QIAGEN
- Abbott
- Merck KGaA
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Neurological Biomarkers Market – By Product
1.3.2 Europe Neurological Biomarkers Market – By Application
1.3.3 Europe Neurological Biomarkers Market – By End User
1.3.4 Europe Neurological Biomarkers Market – By Country
2. Europe Neurological Biomarkers Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Neurological Biomarkers Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Neurological Biomarkers Market - Europe PEST Analysis
4.3 Expert Opinion
5. Europe Neurological Biomarkers Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rising Prevalence of Neurological Disorders
5.1.2 Progressive Research in Neurological Biomarkers
5.2 Key Market Restraints
5.2.1 Complications Associated with the Use of Neurological Biomarkers
5.3 Market Opportunities
5.3.1 Rising Awareness Regarding Benefits of Early Diagnosis
5.4 Future Trends
5.4.1 Patient Inclination Toward Personalized/Precision Medicine
5.5 Impact analysis
6. Neurological Biomarkers Market – Europe Analysis
6.1 Europe Neurological Biomarkers Market Revenue Forecasts and Analysis
7. Europe Neurological Biomarkers Market Analysis And Forecasts To 2027 – By Product
7.1 Overview
7.2 Europe Neurological Biomarkers market, By Product 2019 & 2027 (%)
7.2.1 Europe Neurological Biomarkers Market Revenue and Forecasts to 2027, By Product (US$ Mn)
7.3 Proteomics Biomarker
7.3.1 Overview
7.3.2 Europe Proteomics Biomarker Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Genomics Biomarker
7.4.1 Overview
7.4.2 Europe Genomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Metabolomics Biomarker
7.5.1 Overview
7.5.2 Europe Metabolomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Imaging Biomarker
7.6.1 Overview
7.6.2 Europe Imaging Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.7 Others
7.7.1 Overview
7.7.2 Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
8. Europe Neurological Biomarkers Market Analysis – By Application
8.1 Overview
8.2 Europe Neurological Biomarkers Market, By Application 2019-2027 (%)
8.2.1 Europe Neurological Biomarkers Market Revenue and Forecasts to 2027, By Application (US$ Mn)
8.3 Alzheimer’s Disease
8.3.1 Overview
8.3.2 Europe Alzheimer’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Parkinson’s Disease
8.4.1 Overview
8.4.2 Europe Parkinson’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Schizophrenia
8.5.1 Overview
8.5.2 Europe Schizophrenia Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Huntington's Disease
8.6.1 Overview
8.6.2 Europe Huntington's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Spinal Muscular Atrophy
8.7.1 Overview
8.7.2 Europe Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Others
8.8.1 Overview
8.8.2 Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
9. Europe Neurological Biomarkers Market Analysis – By End User
9.1 Overview
9.2 Europe Neurological Biomarkers Market, By End User 2019-2027 (%)
9.2.1 Europe Neurological Biomarkers Market Revenue and Forecasts to 2027, By End User (US$ Mn)
9.3 Pharmaceutical and Biotechnology Companies
9.3.1 Overview
9.3.2 Europe Pharmaceutical and Biotechnology Companies Market Revenue and Forecasts to 2027 (US$ Mn)
9.4 Clinical Diagnostics
9.4.1 Overview
9.4.2 Europe Clinical Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Research Organizations
9.5.1 Overview
9.5.2 Europe Research Organizations Market Revenue and Forecasts to 2027 (US$ Mn)
10. Neurological Biomarkers Market Revenue and Forecasts To 2027 – Geographical Analysis
10.1 Europe: Neurological Biomarker Market
10.1.1 Overview
10.1.2 Europe: Neurological Biomarker Market - Revenue and Forecast to 2027 (USD Million)
10.1.3 Europe: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)
10.1.4 Europe: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)
10.1.5 Europe: Neurological Biomarker Market, by End-User, 2018–2027 (USD Million)
10.1.6 Europe: Neurological Biomarker Market, by Country, 2019& 2027 (%)
10.1.7 Germany: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.1 Germany: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.7.2 Germany: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)
10.1.7.3 Germany: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)
10.1.7.4 Germany: Neurological Biomarker Market, by End-User, 2018–2027 (USD Million)
10.1.8 United Kingdom: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.1 United Kingdom: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.8.2 United Kingdom: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)
10.1.8.3 United Kingdom: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)
10.1.8.4 United Kingdom: Neurological Biomarker Market, by End-User, 2018–2027 (USD Million)
10.1.9 France: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.1 France: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.9.2 France: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)
10.1.9.3 France: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)
10.1.9.4 France: Neurological Biomarker Market, by End-User, 2018–2027 (USD Million)
10.1.10 Spain: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.10.1 Spain: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.10.2 Spain: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)
10.1.10.3 Spain: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)
10.1.10.4 Spain: Neurological Biomarker Market, by End-User, 2018–2027 (USD Million)
10.1.11 Italy: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.11.1 Italy: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
10.1.11.2 Italy: Neurological Biomarker Market, by Product, 2018–2027 (USD Million)
10.1.11.3 Italy: Neurological Biomarker Market, by Application, 2018–2027 (USD Million)
10.1.11.4 Italy: Neurological Biomarker Market, by End-User, 2018–2027 (USD Million)
11. Impact of COVID-19 Pandemic on Europe Neurological Biomarkers Market
11.1 Europe: Impact Assessment Of COVID-19 Pandemic
12. Company Profiles
12.1 Myriad Genetics, Inc.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 QIAGEN
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 MERCK KGaA
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Thermo Fisher Scientific Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Abbott
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
13. Appendix
13.1 About the Insight Partners
13.2 Word Index
LIST OF TABLES
Table 1. Europe Neurological Biomarkers Market Revenue and Forecasts To 2027, By Product (US$ Mn)
Table 2. Europe Neurological Biomarkers Market Revenue and Forecasts To 2027, By Application (US$ Mn)
Table 3. Europe Neurological Biomarkers Market Revenue and Forecasts To 2027, By End User (US$ Mn)
Table 4. Europe Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 5. Europe Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 6. Europe Neurological Biomarker Market, by End-User– Revenue and Forecast to 2027 (USD Million)
Table 7. US Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 8. US Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 9. US Neurological Biomarker Market, by End-User– Revenue and Forecast to 2027 (USD Million)
Table 10. Canada Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 11. Canada Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 12. Canada Neurological Biomarker Market, by End-User– Revenue and Forecast to 2027 (USD Million)
Table 13. Mexico Neurological Biomarker Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 14. Mexico Neurological Biomarker Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 15. Mexico Neurological Biomarker Market, by End-User– Revenue and Forecast to 2027 (USD Million)
Table 16. List of Abbreviation
LIST OF FIGURES
Figure 1. Neurological Biomarkers Market Segmentation
Figure 2. Europe Neurological Biomarkers Market Overview
Figure 3. Genomic Biomarkers Segment Held Largest Share of Neurological Biomarker Market
Figure 4. US is Expected to Show Remarkable Growth During the Forecast Period
Figure 5. Europe Neurological Biomarkers Market - Leading Country Markets (US$ Mn)
Figure 6. Neurological Biomarkers Market - Europe PEST Analysis
Figure 7. Neurological Biomarkers Market Impact Analysis Of Driver And Restraints
Figure 8. Europe Neurological Biomarkers market – Revenue Forecasts and Analysis – 2019- 2027
Figure 9. Europe Neurological Biomarkers market, By Product 2019 & 2027 (%)
Figure 10. Europe Proteomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 11. Europe Genomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 12. Europe Metabolomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 13. Europe Imaging Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 14. Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 15. Europe Neurological Biomarkers Market, by Application 2019 & 2027 (%)
Figure 16. Europe Alzheimer’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 17. Europe Parkinson’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 18. Europe Schizophrenia Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 19. Europe Huntington's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 20. Europe Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 21. Europe Others Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 22. Europe Neurological Biomarkers Market, by End User 2019 & 2027 (%)
Figure 23. Europe Pharmaceutical and Biotechnology Companies Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 24. Europe Clinical Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 25. Europe Research Organizations Market Revenue and Forecasts to 2027 (US$ Mn)
Figure 26. Europe: Neurological Biomarker Market, by Key Country – Revenue (2019) (USD Million)
Figure 27. Europe Neurological Biomarker Market Revenue and Forecast to 2027 (USD Million)
Figure 28. Europe: Neurological Biomarker Market, by Country, 2019 & 2027 (%)
Figure 29. US: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
Figure 30. Canada: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
Figure 31. Mexico: Neurological Biomarker Market – Revenue and Forecast to 2027 (USD Million)
Figure 32. Impact of COVID-19 Pandemic in Europen Country Markets
- Thermo Fisher Scientific, Inc
- Myriad Genetics
- QIAGEN
- Abbott
- Merck KGaA
- To understand the neurological biomarkers market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for neurological biomarkers market
- Efficiently plan M&A and partnership deals in neurological biomarkers market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form neurological biomarkers market
- Obtain market revenue forecast for market by various segments from 2019 to 2027 in Europe region.